Phathom Pharmaceuticals Confirms No Decrease in Lead Shareholder's Ownership After 13D Filing Administrative Update

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 20 2025

0mins

Source: Globenewswire

Frazier Life Sciences Filing: Phathom Pharmaceuticals announced that Frazier Life Sciences will file a Schedule 13D today, which includes administrative changes but does not indicate a reduction in ownership by Frazier funds or individuals.
Clarification of Reporting Changes: The upcoming filing may show different holdings and percentages due to clarifications in Frazier's reporting approach, rather than any sale of shares.
About Phathom Pharmaceuticals: Phathom is a biopharmaceutical company focused on developing treatments for gastrointestinal diseases, notably marketing vonoprazan under the brand VOQUEZNA for various GERD-related conditions.
Contact Information: Media and investor inquiries can be directed to Nick Benedetto and Eric Sciorilli via provided contact details.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free